Caisse DE Depot ET Placement DU Quebec Lowers Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Caisse DE Depot ET Placement DU Quebec decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 31.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 234,589 shares of the medical research company's stock after selling 109,479 shares during the quarter. Caisse DE Depot ET Placement DU Quebec owned about 0.06% of Thermo Fisher Scientific worth $122,040,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Howard Capital Management Group LLC boosted its holdings in shares of Thermo Fisher Scientific by 0.5% in the 3rd quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company's stock worth $33,759,000 after purchasing an additional 286 shares during the period. Principal Financial Group Inc. increased its position in Thermo Fisher Scientific by 22.1% during the third quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company's stock valued at $771,876,000 after acquiring an additional 225,568 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Thermo Fisher Scientific in the third quarter valued at $638,000. Anchor Investment Management LLC boosted its stake in shares of Thermo Fisher Scientific by 1.7% during the 3rd quarter. Anchor Investment Management LLC now owns 11,366 shares of the medical research company's stock worth $7,031,000 after purchasing an additional 195 shares during the period. Finally, World Investment Advisors LLC raised its position in Thermo Fisher Scientific by 3.8% in the 3rd quarter. World Investment Advisors LLC now owns 15,088 shares of the medical research company's stock worth $9,333,000 after purchasing an additional 548 shares during the period. Institutional investors own 89.23% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Barclays cut their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. Robert W. Baird decreased their target price on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. Raymond James reiterated an "outperform" rating and set a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Finally, Argus reduced their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Five investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $607.43.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the transaction, the executive vice president now owns 16,363 shares in the company, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the sale, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. The trade was a 7.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 24,200 shares of company stock valued at $13,235,041 in the last three months. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Up 0.9 %

Shares of NYSE:TMO traded up $3.80 during trading on Friday, reaching $423.69. The stock had a trading volume of 2,492,422 shares, compared to its average volume of 1,769,322. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $159.94 billion, a P/E ratio of 25.63, a PEG ratio of 2.99 and a beta of 0.86. The firm's 50-day simple moving average is $476.15 and its 200 day simple moving average is $521.16. Thermo Fisher Scientific Inc. has a one year low of $409.85 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business's revenue for the quarter was up .2% on a year-over-year basis. During the same period in the previous year, the company earned $5.11 earnings per share. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were paid a dividend of $0.43 per share. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.41%. Thermo Fisher Scientific's payout ratio is presently 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.